Early Detection and Recurrence of Colorectal Adenomas by Combination of Eight Cancer-Associated Biomarkers in Plasma

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/gutjnl-2015-310912
   PubMed Web of Science ®Google Scholar
• Wolf A, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–281. doi:10.3322/caac.21457
   PubMed Web of Science ®Google Scholar
• Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637–1649. doi:10.1136/gutjnl-2014-309086
   PubMed Web of Science ®Google Scholar
• Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106–1114. doi:10.1056/NEJMoa1300720
   PubMed Web of Science ®Google Scholar
• Morson BC. The evolution of colorectal carcinoma. Clin Radiol. 1984;35(6):425–431. doi:10.1016/S0009-9260(84)80033-1
   Web of Science ®Google Scholar
• Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 2000;343(3):162–168. doi:10.1056/NEJM200007203430301
   PubMed Web of Science ®Google Scholar
• Calderwood AH, Lasser KE, Roy HK. Colon adenoma features and their impact on risk of future advanced adenomas and colorectal cancer. World J Gastrointest Oncol. 2016;8(12):826–834. doi:10.4251/wjgo.v8.i12.826
   PubMed Web of Science ®Google Scholar
• Hisabe T, Hirai F, Matsui T. Development and progression of colorectal cancer based on follow-up analysis. Dig Endosc. 2014;26:73–77. doi:10.1111/den.12276
   Web of Science ®Google Scholar
• Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–573. doi:10.1002/cncr.24760
   PubMed Web of Science ®Google Scholar
• Park DI, Ryu S, Kim Y-H, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105(9):2017–2025. doi:10.1038/ajg.2010.179
   PubMed Web of Science ®Google Scholar
• Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49(14):3049–3054. doi:10.1016/j.ejca.2013.04.023
   PubMed Web of Science ®Google Scholar
• Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142(2):248–e26. doi:10.1053/j.gastro.2011.10.031
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Eng J Med. 2014;370(14):1287–1297. doi:10.1056/NEJMoa1311194
   PubMed Web of Science ®Google Scholar
• Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317–325. doi:10.1136/gutjnl-2012-304149
   PubMed Web of Science ®Google Scholar
• Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30(5):830–833. doi:10.1111/jgh.12855
   PubMed Web of Science ®Google Scholar
• Ma MX, Bourke MJ. Sessile serrated adenomas: how to detect, characterize and resect. Gut Liver. 2017;11(6):747–760. doi:10.5009/gnl16523
   Web of Science ®Google Scholar
• Loughrey MB, Shepherd NA. Problematic colorectal polyps: is it cancer and what do I need to do about it? Surg Pathol Clin. 2017;10(4):947–960. doi:10.1016/j.path.2017.07.009
   Google Scholar
• Parente F, Boemo C, Ardizzoia A, et al. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Endoscopy. 2013;45(01):27–34. doi:10.1055/s-0032-1325800
   Web of Science ®Google Scholar
• Klabunde C, Blom J, Bulliard J-L, et al. Participation rates for organized colorectal cancer screening programmes: an international comparison. J Med Screen. 2015;22(3):119–126. doi:10.1177/0969141315584694
   PubMed Web of Science ®Google Scholar
• van der Vlugt M, Grobbee EJ, Bossuyt PM, et al. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. Br J Cancer. 2017;116(1):44–49. doi:10.1038/bjc.2016.399
   Web of Science ®Google Scholar
• Song -L-L, Li Y-M. Current noninvasive tests for colorectal cancer screening: an overview of colorectal cancer screening tests. World J Gastrointest Oncol. 2016;8(11):793–800. doi:10.4251/wjgo.v8.i11.793
   PubMed Web of Science ®Google Scholar
• Erben V, Bhardwaj M, Schrotz-King P, Brenner H. Metabolomics biomarkers for detection of colorectal neoplasms: a systematic review. Cancers. 2018;10(8):246. doi:10.3390/cancers10080246
   Web of Science ®Google Scholar
• Nikolaou S, Qiu S, Fiorentino F, Rasheed S, Tekkis P, Kontovounisios C. Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctology. 2018;22(7):481–498. doi:10.1007/s10151-018-1820-3
   PubMed Web of Science ®Google Scholar
• Chen H, Qian J, Werner S, Cuk K, Knebel P, Brenner H. Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer. Clin Epidemiol. 2017;9:517–526. doi:10.2147/CLEP.S144171
   Web of Science ®Google Scholar
• Werner S, Krause F, Rolny V, et al. Evaluation of a 5-marker blood test for colorectal cancer early detection in a colorectal cancer screening setting. Clin Cancer Res. 2016;22(7):1725–1733. doi:10.1158/1078-0432.CCR-15-1268
   PubMed Web of Science ®Google Scholar
• Wild N, Andres H, Rollinger W, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16(24):6111–6121. doi:10.1158/1078-0432.CCR-10-0119
   PubMed Web of Science ®Google Scholar
• Semaan A, van Ellen A, Meller S, et al. SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas. Clin Epigenetics. 2016;8:100. doi:10.1186/s13148-016-0267-5
   PubMed Web of Science ®Google Scholar
• Uratani R, Toiyama Y, Kitajima T, et al. Diagnostic potential of cell-free and exosomal MicroRNAs in the identification of patients with high-risk colorectal adenomas. PLoS One. 2016;11(10):10. doi:10.1371/journal.pone.0160722
   Web of Science ®Google Scholar
• Wang Z-H, Ren -L-L, Zheng P, et al. miR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy. Cancer Prev Res. 2014;7(6):607–616. doi:10.1158/1940-6207.CAPR-13-0426
   Web of Science ®Google Scholar
• Wilhelmsen M, Christensen IJ, Rasmussen L, et al. Detection of colorectal neoplasia: combination of eight blood-based, cancer-associated protein biomarkers. Int J Cancer. 2017;140(6):1436–1446. doi:10.1002/ijc.30558
   PubMed Web of Science ®Google Scholar
• Feng Y, Li Y, Dai W, Mo S, Li Q, Cai S. Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing colorectal cancer: analysis of 78 cases. Cell Physiol Biochem. 2018;51(5):2052–2064. doi:10.1159/000495824
   Google Scholar
• Wang YR, Yan JX, Wang LN. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer. J Can Res Ther. 2014;10(8):307–309. doi:10.4103/0973-1482.151538
   Web of Science ®Google Scholar
• Kim NH, Lee MY, Park JH, et al. Serum CEA and CA 19-9 levels are associated with the presence and severity of colorectal neoplasia. Yonsei Med J. 2017;58(5):918–924. doi:10.3349/ymj.2017.58.5.918
   PubMed Web of Science ®Google Scholar
• Thomsen M, Skovlund E, Sorbye H, et al. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. Br J Cancer. 2018;118(12):1609–1616. doi:10.1038/s41416-018-0115-9
   Web of Science ®Google Scholar
• Giessen-jung C, Nagel D, Glas M, et al. Preoperative serum markers for individual patient prognosis in stage I-III colon cancer. Tumor Biol. 2015;36(10):7897–7906. doi:10.1007/s13277-015-3522-z
   Google Scholar
• Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, Huo X. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep. 2018;8:245.
   Web of Science ®Google Scholar
• Duffy M, Lamerz R, Haglund C, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134(11):2513–2522. doi:10.1002/ijc.28384
   PubMed Web of Science ®Google Scholar
• Lim DH, Lee JH, Kim JW. Feasibility of CYFRA 21-1 as a serum biomarker for the detection of colorectal adenoma and advanced colorectal adenoma in people over the age of 45. J Clin Lab Anal. 2018;32(1):e22163. doi:10.1002/jcla.22163
   PubMed Web of Science ®Google Scholar
• Lee JH. Clinical usefulness of serum CYFRA 21–1 in patients with colorectal cancer. Nucl Med Mol Imaging. 2013;47(3):181–187. doi:10.1007/s13139-013-0218-4
   Google Scholar
• Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836(2):245–254. doi:10.1016/j.bbcan.2013.07.002
   PubMed Web of Science ®Google Scholar
• Schneider C, Bodmer M, Jick SS, Meier CR. Colorectal cancer and markers of anemia. Eur J Cancer Prev. 2018;27(6):530–538. doi:10.1097/CEJ.0000000000000397
   PubMed Web of Science ®Google Scholar
• Tao L, Jin L, Dechun L, Hongqiang Y, Changhua K, Guijun L. Galectin-3 expression in colorectal cancer and its correlation with clinical pathological characteristics and prognosis. Open Med. 2017;12(1):226–230. doi:10.1515/med-2017-0032
   Web of Science ®Google Scholar
• Meng C, Yin X, Liu J, Tang K, Tang H, Liao J. TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: a meta-analysis. PLoS One. 2018;13(11):11. doi:10.1371/journal.pone.0207039
   Web of Science ®Google Scholar
• Nielsen HJ, Brünner N, Jorgensen LN, et al. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol. 2011;46(1):60–69. doi:10.3109/00365521.2010.513060
   PubMed Web of Science ®Google Scholar
• Christensen IJ, Brünner N, Dowell B, et al. Plasma TIMP-1 and CEA as markers for detection of primary colorectal cancer: a prospective validation study including symptomatic and non-symptomatic individuals. Anticancer Res. 2015;35(9):4935–4941.
   Web of Science ®Google Scholar
• Rasmussen L, Christensen IJ, Herzog M, Micallef J, Nielsen HJ. Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer. Oncotarget. 2018;9(12):10247–10258. doi:10.18632/oncotarget.21908
   Google Scholar